GLP-1 and GIP Mechanisms and Effects

Introduction to GLP-1 and GIP

• GLP-1 and GIP are incretin hormones that regulate glucose homeostasis primarily by stimulating insulin secretion from pancreatic β cells in a glucose-dependent manner, with additional effects on glucagon secretion, gastric emptying, and appetite regulation 1, 2

Physiological Origin and Metabolism

• GLP-1 is released by L-enteroendocrine cells in the terminal ileum and proximal colon in response to glucose load and triglycerides 3, 4
• GLP-1 is also secreted by islet cells and neurons in the nucleus tractus solitarius in the brainstem 4
• GIP is released from the small intestine in response to meals 5
• Natural GLP-1 has a very short half-life (approximately 2 minutes) due to rapid cleavage by dipeptidyl peptidase-4 (DPP-4) enzyme 4

Mechanism of Action on Pancreatic Function

• Both GLP-1 and GIP bind to specific G-protein coupled receptors (GLP-1R and GIPR) on pancreatic β cells 2
• This stimulates insulin secretion only when blood glucose levels are elevated, explaining the low risk of hypoglycemia with GLP-1 receptor agonists 1, 2
• GLP-1 receptor agonists may promote β cell proliferation and protect against apoptosis, potentially preserving pancreatic β cell mass 6

Effects on Glucagon Secretion

• GLP-1 receptor activation inhibits glucagon secretion from pancreatic α cells, reducing hepatic glucose production 1
• GIP receptor activation has a dual effect on glucagon: augments glucagon secretion during euglycemia or hypoglycemia and inhibits glucagon secretion during hyperglycemia 2

Gastrointestinal Effects

• Gastric emptying is a primary determinant of postprandial glycemic response 6
• GLP-1 receptor activation delays gastric emptying by inhibiting gastric peristalsis while increasing pyloric tone 6
• These actions result in reduced gastric contractions, delayed gastric emptying, reduced gastric acid secretion, and increased gastric volumes 6, 7

Tachyphylaxis with Continuous Exposure

• The effect of GLP-1 on gastric emptying shows tachyphylaxis (diminishing response) with continuous exposure 7
• Short-acting GLP-1 receptor agonists maintain their effect on gastric emptying longer than long-acting ones 7

Pharmacological Applications

• Dual GIP/GLP-1 receptor agonists like tirzepatide have shown greater reductions in HbA1c and body weight compared to GLP-1 receptor agonists alone 2

Clinical Implications

• The glucose-dependent nature of insulin stimulation by both GLP-1 and GIP explains the low risk of hypoglycemia with incretin-based therapies 2
• GLP-1's effect on slowing gastric emptying contributes to increased satiety and weight loss 6

Incretin Hormones in Metabolic Regulation

Gastrointestinal Effects

• GIP does not significantly affect gastric emptying 8

Additional Metabolic Effects

• GLP-1 receptors located in the hypothalamus and brainstem nuclei mediate appetite, satiety, energy intake and expenditure 9

Therapeutic Applications

• GLP-1 receptor agonists, such as those recommended by the American Diabetes Association, are effective for both diabetes and weight management 9, 10
• The American Heart Association acknowledges that GLP-1 receptor agonists have demonstrated cardiovascular benefits in high-risk patients 9

Key Pathophysiological Role

• Both GIP and GLP-1 hormones are involved in dumping syndrome after gastric surgery, with enhanced release contributing to early dumping symptoms and exaggerated GLP-1 response mediating hyperinsulinemic hypoglycemia characteristic of late dumping syndrome 8, 11

Mechanism of Action of Tirzepatide

Dual Receptor Activation

• The American Diabetes Association notes that tirzepatide activates the G-protein coupled GLP-1 receptor on pancreatic β cells, increasing intracellular calcium and leading to insulin exocytosis in a glucose-dependent manner, with a binding affinity approximately five times less than endogenous GLP-1 12
• The European Association for the Study of Diabetes recommends considering tirzepatide due to its glucose-dependent nature of insulin stimulation, which explains the low risk of hypoglycemia 13

Metabolic and Appetite Regulation

• The Endocrine Society suggests that both GLP-1 and GIP receptors, located in the hypothalamus and brainstem nuclei, mediate appetite, satiety, energy intake, and expenditure, contributing to weight loss 14

Superior Efficacy Through Dual Agonism

• The American College of Cardiology recommends tirzepatide as it produced greater reductions in HbA1c and body weight compared with selective GLP-1 receptor agonists like semaglutide and dulaglutide, with improvements in insulin sensitivity and insulin secretory responses 12, 13

Clinical Implications

• The American Association of Clinical Endocrinologists notes that the glucose-dependent mechanism of both GIP and GLP-1 receptor activation means insulin secretion is significantly attenuated when plasma glucose is not elevated, minimizing hypoglycemia risk 13